Analysts set CNY 280.14 target for Mindray stock

Published on 10/08/2026 at 12:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Thirty of 32 analysts recommend Mindray stock. First-half revenue rose 6.00 percent to CNY 17.75 billion, and net profit reached CNY 4.80 billion.

Mindray, CNE100003G67, Illustration mit AI erstellt.

Analysts list a CNY 280.14 average target for Mindray stock, based on 32 ratings, while the companys first-half revenue rose 6.00 percent to CNY 17.75 billion. Eulerpool lists 30 Buy ratings, two Hold ratings and no Sell ratings for Shenzhen Mindray Bio-Medical Electronics.

International sales lead growth

The companys latest reported period was the first half of 2026. According to min.news, net profit attributable to shareholders reached CNY 4.80 billion, while operating cash flow was CNY 4.88 billion, up 24.35 percent year over year.

International revenue increased 13.67 percent to CNY 9.47 billion and represented more than 53 percent of first-half revenue, according to min.news. The international figure therefore grew more than twice as fast as total revenue, making overseas execution the clearest operating support in the reported numbers.

Medical devices remain the core

Mindrays product mix spans patient monitoring, in-vitro diagnostics and medical imaging. The first-half in-vitro diagnostics business generated CNY 6.87 billion, up 9.58 percent year over year, while emerging businesses produced CNY 3.11 billion, up 19.59 percent, min.news reported.

The next scheduled reporting date is October 26, 2026, according to Eulerpool. That date gives the CNY 280.14 consensus target a defined checkpoint, while the first-half figures show that revenue growth and profit growth are moving at different speeds.

Shenzhen valuation stays below target

On the Shenzhen Stock Exchange, the stock was last at CNY 157.60 on October 8, 2026 at 3:04 p.m. CST. The quote sits within a CNY 130.66 to CNY 248.98 52-week range, while market capitalization stood at CNY 191.1 billion on the same date.

TradingView identifies the listing as Shenzhen Stock Exchange ticker 300760 and classifies Mindray in health technology and medical specialties. The CNY 280.14 average target is 77.99 percent above the CNY 157.60 market price, so the consensus depends on stronger future execution than the first-half profit number alone.